Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
Status:
Recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
The primary objective of the induction phase of the study is to compare treatment retention
of participants following rapid induction or standard of care (SoC) induction onto
extended-release buprenorphine.
The primary objective of the maintenance phase is to compare the efficacy of 100 mg and 300
mg maintenance doses of extended-release buprenorphine administered every 4 weeks.